



## Recent Advances in the Development of Hybrid Drugs

Guest Editors:

### Dr. Tânia S. Morais

Centro de Química Estrutural,  
Institute of Molecular Sciences,  
Instituto Superior Técnico,  
Universidade de Lisboa, Av.  
Rovisco Pais, 1049-001 Lisboa,  
Portugal

### Dr. Ana M. de Matos

Centro de Química Estrutural,  
Institute of Molecular Sciences,  
Faculdade de Ciências da  
Universidade de Lisboa, 1749-016  
Lisboa, Portugal

Deadline for manuscript  
submissions:

**closed (20 April 2024)**

### Message from the Guest Editors

Dear Colleagues,

Hybrid drug development is a research field that is currently expanding. For a wide community of researchers around the world, the combination of two or more pharmacophores and/or drug-directing moieties in the same molecule is an attractive strategy for the design of new compounds with optimized pharmacodynamic profiles, and has already delivered promising results in the contexts of multidrug-resistant cancers, emerging antimicrobial-resistant bacteria, and others.

Because of its undeniable potential, more and more researchers are integrating molecular hybridization into their strategic drug development approaches. Hence, this Special Issue of Pharmaceutics welcomes original research articles, communications and review articles dedicated to major advancements, breakthroughs and challenges in the design, synthesis and biological evaluation of organic, inorganic and organometallic hybrid drugs. Medicinal chemists working across all therapeutic areas are encouraged to contribute with research or literature overviews on this topic.

Dr. Tânia S. Morais

Dr. Ana M. de Matos

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Patrick J. Sinko

Ernest Mario School of  
Pharmacy, Rutgers, The State  
University of New Jersey, William  
Levine Hall, Room 225C, 160  
Frelinghuysen Road, Piscataway,  
NJ 08854-8020, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceutics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma